# Alex Brownstein

Alex Brownstein analyzes advertising platforms and marketing trends, explaining what the numbers mean for advertisers. Their posts cover topics including Spotify’s ad business, pharmaceutical advertising on TV, and how companies should measure investment in AI.

- Profile: https://b2binfluencer.marketing/creators/alex-brownstein/
- LinkedIn: https://www.linkedin.com/in/ahbrownstein
- LinkedIn followers: 9,051
- Topics: artificial-intelligence, ai-marketing, retail-media
- Based on 10 dated posts, latest 2026-10-08

## Summary

They are most useful for data-led explanations that connect advertising trends to measurement and business choices.

- Best for: A healthcare marketing analytics company wanting a conference talk on platform ad measurement.
- Not for: A consumer wellness brand seeking sponsored creator reach, coupon redemptions, or sign-ups.
- Check first: Confirm whether they accept sponsorships and ask for LinkedIn follower demographics and engagement.

### Takeaways

- Spotify's 1% ad growth bundles growing programmatic with shrinking direct sales.
- A grocery delivery deal is not permission to use prescription data.
- Ask what result finance would fund again for AI marketing spend.

## Main ideas

- **A blended growth number hides the business inside it**: Brownstein's recurring move is to split a summary metric into the lines underneath and ask which one is actually moving. In the Spotify post, 1% ad-revenue growth is not a verdict on the ad business but the net of a fast-growing programmatic line and a shrinking direct-sales line. They keep the counter-evidence in view: Spotify has guided to advertising acceleration before and missed, and audio has sold at lower CPMs than visual formats for years. Their conclusion is that the infrastructure rebuild looks finished, while demand has not caught up. The practical question: which number does a client believe they are reading?
- **A delivery deal is not permission to use health data**: Brownstein separates the commercial logic of a retail arrangement from the rules that determine whether a marketer can act on it. They argue that combining groceries and eligible prescriptions gives Kroger a scheduled reason for customers to reopen its app every 30 or 90 days without another coupon, then lay out the obstacles. HIPAA requires authorization for this use of prescription records; Meta and Google restrict health targeting; Instacart bans prescription marketing; and Kroger has no published pharmaceutical policy or product. For comparison, Brownstein lays out Amazon's pharmacy position: in the market since 2020, One Medical acquired in 2023, a $19.8 billion ad quarter, and an Evercore estimate of $2 billion in 2024 pharmacy sales against industry estimates of 1 to 2% US pharmacy share. The recommendation remains conditional, with Brownstein ending on the measures they would watch rather than a verdict.
- **Ask what result finance would fund again**: After EMARKETER's Future of Digital Summit, Brownstein asks what a CMO investing in AI visibility or paid AI ads could show a CFO to call the investment successful—and what would need to be true to move that spending from an experimental budget to a recurring one. Their starting point is for marketing and finance to agree on a result they would fund again. That may require changing how the company works as AI reshapes what full-funnel means and who participates. Brownstein frames this as an open question, not a settled position. The specific perspectives they relay belong to other speakers: Emily Tisch Sussman on women's sports sponsorship shifting from a community expense to dedicated marketing investment; Melissa H. on consumers researching with AI and then checking answers against sources they trust; John Nitti on the mismatch between conversational AI and search-budget cost-per-click expectations; Heather Physioc on websites, earned media and customer-created content contributing to discovery; and Louis Giagrande on connecting internal teams running similar AI projects. Brownstein adds the renewal problem: an experiment can rely on people finding time around their regular jobs, but funding it again next year means making that work part of the job.

## Work to read

- [Spotify's 1% ad growth is two numbers pretending to be one](https://www.linkedin.com/posts/ahbrownstein_spotify-has-494-million-ad-supported-users-activity-7499281871936204801-QPQi)
- [Pharma's TV decline, and why a grocery delivery deal is not targeting permission](https://www.linkedin.com/posts/ahbrownstein_pharma-led-us-national-linear-tv-ad-spending-activity-7503525674427752448-noqO)
- [Two questions to put to a CFO about AI marketing spend](https://www.linkedin.com/posts/ahbrownstein_i-left-emarketers-future-of-digital-summit-activity-7506017172905803776-Nenj)

## Brand relationships

- **Spotify** (mention)
- **Kroger** (mention)
- **Instacart** (mention)
- **Amazon** (mention)
- **EMARKETER** (mention)

## Partnerships

Alex Brownstein’s LinkedIn posts analyze advertising and marketing decisions, including Spotify’s ad-revenue mix, pharmaceutical advertising and retail pharmacy, and how companies might measure investment in AI. The posts don’t establish whether they take paid partnerships; ask about partnership formats and how to make a commercial inquiry.

## Alternatives

- Guru Hariharan: Choose Guru Hariharan when the need shifts from pharma advertising to AI-driven retail media performance and AI risk. The Amazon post gives a concrete measurement story: $19.8 billion in ad revenue for a quarter, and shoppers who interact with AI-powered Sponsored Prompts convert 48% higher and spend 21% more per transaction. It argues that product-data quality now determines whether a brand captures that lift. The AI-risk post adds governance failures, hallucination costs, bias litigation and insurance gaps. For a conference talk on how AI changes platform ad measurement and what can go wrong, this is closer to the room than Alex's pharma TV and health-permission material.
- Don “eCommerce” Brett: Choose Don Brett when the client needs a CPG retail-media and ecommerce growth story rather than a pharma advertising analyst. The two posts supply comparable retailer data: in Q1 2026, median comparable sales growth was +2.9% across 47 retailers and median digital growth was +12.5% across 22 companies reporting it. Walmart showed +2.6% comparable sales against +24% digital growth; Kroger +1.0% against +19%; Costco +6.8% against +21%; Home Depot +1.3% against +11%. The Amazon grocery post adds shopper frequency and basket data. For a talk on where retail media budgets should follow growth, this is a stronger fit than Alex's pharma-specific examples.
- Buhir Rafiq: Choose Buhir Rafiq when the need is pharmacy business finance and operations, not healthcare marketing analytics. Both posts compare in-house bookkeeping with outsourced specialist pharmacy accounting and recommend a hybrid model for NHS statement reconciliation, VAT, HMRC compliance, management accounts and tax planning. For a conference talk aimed at pharmacy owners about building a finance function, this is more directly useful than Alex's advertising analysis.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/